Reported 8 months ago
Novo Nordisk's weight-loss drug Wegovy has been approved in China, targeting overweight and obese individuals in the country. With the high prevalence of obesity in China, the company aims to tap into this market despite facing competition and potential patent expiration challenges. The drug's approval in China marks the 12th global market where Wegovy is available, with Novo Nordisk and Eli Lilly racing to meet the growing demand in the weight-loss market.
Source: YAHOO